President's Column
ASH Marks 10 Years of Sustained Focus on Sickle Cell Disease
"With its emphasis on serving both clinicians and scientists and partnering with other stakeholders to help conquer blood diseases, ASH’s work on the SCD front embodies the very mission of the Society," writes ASH President Belinda R. Avalos, MD.
Minimal Residual Disease-Guided Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
The MIDAS trial is an elegant example of response-directed therapy that can be used to deepen response after induction or minimize toxicity in patients who have already achieved deep responses.
How Gene Therapy Is Set to Transform Hemophilia B Management
A landmark study alleviates some concerns about the durability and long-term safety of scAAV2/8-LP1-hFIXco hemophilia B gene therapy.
Combination of Antibody Drug Conjugate With Bispecific T-Cell Engager for Relapsed Large B-Cell Lymphoma
An ongoing trial points to a future in which novel targeted agents are used “off the shelf” in well-tolerated and highly effective combination regimens that can be administered in the community setting.
